Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer

Abstract

With clear evidence of activity for immune checkpoint inhibitors across the spectrum of solid tumour malignancies, identifying combination therapies to augment their efficacy is a high research priority. In gastro-oesophageal cancer, immune checkpoint inhibitors initially received approval for chemotherapy-refractory gastric cancer,1 then approval for second-line therapy in oesophageal squamous cancer,2,3 and more recently approval in combination with first-line chemotherapy in oesophagogastric cancer.